公开(公告)号：US12085573B2

公开(公告)日：2024-09-10

申请号：US14576944

申请日：2014-12-19

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Martin Hund ,  Maria Schoedl

IPC: G01N33/68 ,  G16H50/30 ,  G16H50/70

CPC classification number: G01N33/689 ,  G16H50/30 ,  G16H50/70 ,  G01N2333/475 ,  G01N2333/515 ,  G01N2333/71 ,  G01N2333/912 ,  G01N2800/368

Abstract: The present invention concerns the field of diagnostic assays for prenatal diagnosis of preeclampsia. In particular, it relates to a method for diagnosing whether a pregnant subject is not at risk for preeclampsia within a short window of time comprising a) determining the amount of at least one angiogenesis biomarker selected from the group consisting of sFlt-1, Endoglin and PlGF in a sample of said subject, and b) comparing the amount with a reference, whereby a subject being not at risk for developing preeclampsia within a short period of time is diagnosed if the amount is identical or decreased compared to the reference in the cases of sFlt-1 and Endoglin and identical or increased in the case of PlGF, wherein said reference allows for making the diagnosis with a negative predictive value of at least about 98%. Further contemplates are devices and kits for carrying out said method.

公开(公告)号：US20200378981A1

公开(公告)日：2020-12-03

申请号：US16998444

申请日：2020-08-20

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Martin Hund ,  Thomas Dieterle ,  Olav Lapaire

IPC: G01N33/68

Abstract: The present invention is directed to a method for predicting the risk of a female subject to develop postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method is based on the determination of the levels of i) sFlt-1 and PlGF, or ii) Endoglin and PlGF in a first sample obtained from said subject before delivery of baby, and a second sample of from said subject obtained after delivery of baby. Moreover, encompassed by the invention are devices and kits for carrying out the method of the present invention.

公开(公告)号：US20230221335A1

公开(公告)日：2023-07-13

申请号：US17916251

申请日：2021-03-30

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Sibylle Berner-Gatz ,  Martin Hund ,  Katharina Buck

IPC: G01N33/68 ,  G16H50/20 ,  G16H50/30

CPC classification number: G01N33/689 ,  G16H50/20 ,  G16H50/30

Abstract: The present invention relates to a method of assessing a female’s risk of having polycystic ovary syndrome (PCOS), a kit for use in assessing a female’s risk of having PCOS, the use of a marker combination in the assessment of a female’s risk of having PCOS, a computer system for use in a method according to the present invention as well as a computer program and a computer-readable storage medium comprising instructions, which when executed by a computer, cause the computer to carry out the method of the present invention.

公开(公告)号：US20220128568A1

公开(公告)日：2022-04-28

申请号：US17463876

申请日：2021-09-01

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Barbara Denk ,  Martin Hund

IPC: G01N33/68 ,  C07K16/22 ,  G01N33/74

Abstract: Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3.

公开(公告)号：US20190227074A1

公开(公告)日：2019-07-25

申请号：US16373098

申请日：2019-04-02

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Barbara Denk ,  Martin Hund

IPC: G01N33/68 ,  G01N33/74

Abstract: Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3.

公开(公告)号：US20180364248A1

公开(公告)日：2018-12-20

申请号：US16110687

申请日：2018-08-23

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Martin Hund ,  Edelgard Anna Kaiser ,  Ursula-Henrike Wienhues-Thelen ,  Dirk Block ,  Johann Karl

IPC: G01N33/68

Abstract: The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.

公开(公告)号：US20160327564A1

公开(公告)日：2016-11-10

申请号：US15216980

申请日：2016-07-22

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Martin Hund ,  Thomas Dieterle ,  Olav Lapaire

IPC: G01N33/68

CPC classification number: G01N33/689 ,  G01N33/6863 ,  G01N2333/515 ,  G01N2333/705 ,  G01N2333/91205 ,  G01N2800/368 ,  G01N2800/50

Abstract: The present invention is directed to a method for predicting the risk of a female subject to develop postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method is based on the determination of the levels of i) sFlt-1 and PlGF, or ii) Endoglin and PlGF in a first sample obtained from said subject before delivery of baby, and a second sample of from said subject obtained after delivery of baby. Moreover, encompassed by the invention are devices and kits for carrying out the method of the present invention.

Abstract translation: 本发明涉及一种预测女性受试者产生产后HELLP综合征，产后先兆子痫或产后子痫风险的方法。 该方法是基于i）sFlt-1和PlGF的水平的确定，或ii）在分娩前从所述受试者获得的第一样品中的内皮糖蛋白和PlGF，以及在分娩后获得的来自所述受试者的第二个样品 宝宝。 此外，本发明包括用于实施本发明的方法的装置和套件。

公开(公告)号：US20140234879A1

公开(公告)日：2014-08-21

申请号：US14264377

申请日：2014-04-29

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Barbara Denk ,  Martin Hund

IPC: G01N33/68 ,  G01N33/74

CPC classification number: G01N33/689 ,  G01N33/74 ,  G01N2800/368 ,  G01N2800/50

Abstract: Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3.

Abstract translation: 与诊断怀孕受试者是否处于在短时间内发展子痫前期和/或早发型先兆子痫的风险有关的诊断方法和工具。 所述方法包括测定所述受试者的第一和第二样品中生物标志物sFlt-1或Endoglin和PIGF的量，所述第一样品在所述第二样品之前获得; 从第一样品中测定的sFlt-1或Endoglin和PIGF的量计算第一比例，以及从第二样品中测定的sFlt-1或Endoglin和PIGF的量的第二比率; 并且比较第一和第二比率的值，由此如果第二比率的值比第一比率的值增加一个因子，则诊断在短时间内处于发展先兆子痫风险的对象 至少约3。